SV2A as a Radioligand Therapy Target
SV2A, synaptic vesicle glycoprotein 2A, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, SV2A staining is highest in neuroendocrine tumors (100% of samples positive), glioma (70% of samples positive) and lung cancer (17% of samples positive). Clinical status: Clinical-stage (up to phase 3, any modality).
Is SV2A a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in neuroendocrine tumors, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SV2A expression in cancer
Protein expression of SV2A across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Neuroendocrine Tumors | 1.00 | High | 100% |
| Glioma | 0.50 | Medium | 70% |
| Lung Cancer | 0.17 | Low | 17% |
| Testicular Cancer | 0.11 | Low | 17% |
| Endometrial Cancer | 0.06 | Low | 8% |
| Pancreatic Cancer | 0.03 | Low | 8% |
Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, lymphoma, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, cervical cancer, prostate cancer, gastric cancer, liver cancer.
Is SV2A internalized?
Nuclens has not yet extracted internalization evidence for SV2A. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
SV2A clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for SV2A yet. Search ClinicalTrials.gov for SV2A trials.
SV2A normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SV2A in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SV2A gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.27 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related neuroendocrine tumors radioligand targets
HER3 (ERBB3) · c-MET (MET) · SSTR2 · STEAP2 · EPCAM · ITGB6 · KIT · FAP
See all radioligand therapy targets in neuroendocrine tumors.
See how SV2A ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.